MiniMed Group Inc (NASDAQ:MMED) Stock Short Interest Climbs 68.7%

Posted by Brenda Bartman on Sep 30th, 2026

MiniMed Group Inc (NASDAQ:MMED – Get Free Report) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totaling 13,594,922 shares, an increase of 68.7% from the August 31st total of 8,060,409 shares. Based on an average daily trading volume, of 2,805,245 shares, the days-to-cover ratio is currently 4.8 days. Approximately 4.8% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp bought a new position in MiniMed Group in the 2nd quarter valued at approximately $6,029,000. Bank of New York Mellon Corp bought a new stake in MiniMed Group during the 2nd quarter worth approximately $1,058,000. Freestone Grove Partners LP acquired a new position in MiniMed Group in the 2nd quarter valued at approximately $1,745,000. J. Goldman & Co LP bought a new position in shares of MiniMed Group during the second quarter valued at $12,412,000. Finally, Readystate Asset Management LP acquired a new position in shares of MiniMed Group during the second quarter worth $4,400,000.

MiniMed Group Price Performance

MMED stock traded down $0.21 during midday trading on Wednesday, reaching $19.83. 157,731 shares of the stock were exchanged, compared to its average volume of 1,310,108. MiniMed Group has a 52 week low of $10.65 and a 52 week high of $24.43. The company has a fifty day moving average price of $20.28 and a 200 day moving average price of $16.25. The stock has a market capitalization of $5.58 billion and a PE ratio of -29.22.

Analyst Ratings Changes

A number of research analysts have issued reports on MMED shares. Wells Fargo & Company lifted their target price on MiniMed Group from $22.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, September 2nd. Weiss Ratings raised shares of MiniMed Group from a “sell (d-)” rating to a “sell (d)” rating in a report on Wednesday, September 9th. Truist Financial initiated coverage on shares of MiniMed Group in a report on Thursday, September 24th. They set a “buy” rating and a $29.00 price target on the stock. Citigroup upped their price objective on shares of MiniMed Group from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 2nd. Finally, Piper Sandler reissued a “neutral” rating and issued a $16.00 price objective on shares of MiniMed Group in a research note on Thursday, June 4th. Fourteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, MiniMed Group presently has an average rating of “Moderate Buy” and an average target price of $24.14.

View Our Latest Research Report on MiniMed Group

About MiniMed Group

(Get Free Report)

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.